Modera Wealth Management LLC Sells 720 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Modera Wealth Management LLC lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,962 shares of the biopharmaceutical company’s stock after selling 720 shares during the quarter. Modera Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $4,521,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Western Wealth Management LLC bought a new position in Regeneron Pharmaceuticals during the first quarter valued at $26,000. Armstrong Advisory Group Inc. raised its stake in shares of Regeneron Pharmaceuticals by 466.7% in the third quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 28 shares during the period. Activest Wealth Management raised its stake in shares of Regeneron Pharmaceuticals by 780.0% in the third quarter. Activest Wealth Management now owns 44 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 39 shares during the period. Alpine Bank Wealth Management bought a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at $34,000. Finally, Mowery & Schoenfeld Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at $29,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Robert W. Baird increased their price target on Regeneron Pharmaceuticals from $742.00 to $761.00 and gave the stock a “neutral” rating in a research note on Friday, July 31st. BMO Capital Markets boosted their price objective on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company an “outperform” rating in a research note on Wednesday, September 9th. Argus raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 price objective on the stock in a report on Thursday, October 1st. Jefferies Financial Group increased their target price on shares of Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Finally, Sanford C. Bernstein increased their target price on shares of Regeneron Pharmaceuticals from $753.00 to $756.00 and gave the stock a “market perform” rating in a research report on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $850.83.

Insider Activity

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,131 shares of the firm’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $857.39, for a total value of $969,708.09. Following the completion of the transaction, the executive vice president directly owned 12,003 shares of the company’s stock, valued at $10,291,252.17. This trade represents a 8.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the transaction, the director owned 603 shares of the company’s stock, valued at $512,550. This trade represents a 39.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 8,093 shares of company stock worth $6,506,845. Insiders own 6.97% of the company’s stock.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations: Regeneron reported $5.12 billion in revenue, up 36.3% year over year and well above the approximately $4.56 billion analyst consensus. Non-GAAP EPS was $20.07, compared with estimates near $16.42 and $11.83 a year earlier. REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
• Positive Sentiment: Strong commercial performance: Sanofi-partnered Dupixent generated robust demand, while U.S. Eylea HD sales increased 62% to $699 million and global Libtayo sales rose 51% to $550 million. The results suggest Regeneron’s product portfolio is offsetting competitive and pricing pressures in older treatments. Regeneron Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: Pipeline and strategic momentum: Regeneron highlighted progress toward upcoming FDA catalysts, expanded its Sanofi collaboration with next-generation long-acting immunology antibodies and received a $1 billion upfront payment to be recognized as collaboration revenue. A new Phase 2 cemiplimab combination study also expands its skin-cancer pipeline. Regeneron Expands Skin Cancer Pipeline With New Cemiplimab Combo Trial
• Neutral Sentiment: Management characterized 2026 as potentially one of Regeneron’s strongest years, and analysts have raised some expectations following the earnings beat. Investors will now focus on whether Dupixent growth and new launches can remain durable.
• Negative Sentiment: Eylea 2 mg remains exposed to biosimilar competition, while at least one analyst recently lowered Regeneron’s price target from $900 to $850. After the sharp upward move, valuation and the need for continued execution could create near-term volatility. Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Trading Up 13.3%

Shares of REGN opened at $927.89 on Friday. The business’s 50-day moving average price is $793.30 and its 200-day moving average price is $738.05. Regeneron Pharmaceuticals, Inc. has a twelve month low of $591.52 and a twelve month high of $935.35. The stock has a market cap of $95.54 billion, a PE ratio of 20.49, a P/E/G ratio of 1.57 and a beta of 0.16. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $4.58 billion. During the same period in the prior year, the firm posted $11.83 earnings per share. The company’s revenue for the quarter was up 36.3% on a year-over-year basis. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 49.10 EPS for the current fiscal year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.